Zacks Research Issues Positive Estimate for BMY Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Analysts at Zacks Research raised their Q4 2026 earnings per share (EPS) estimates for Bristol Myers Squibb in a research report issued to clients and investors on Thursday, February 19th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings per share of $1.46 for the quarter, up from their previous forecast of $1.32. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s Q2 2027 earnings at $1.55 EPS and Q4 2027 earnings at $1.34 EPS.

Several other research analysts also recently weighed in on the stock. Piper Sandler restated an “overweight” rating and issued a $66.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research note on Wednesday, January 28th. Citigroup raised their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Finally, Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their target price for the company from $52.00 to $61.00 in a research note on Monday, December 15th. Nine analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $60.19.

Bristol Myers Squibb Stock Up 0.6%

NYSE BMY opened at $60.66 on Monday. The stock has a market cap of $123.53 billion, a PE ratio of 17.58, a P/E/G ratio of 0.17 and a beta of 0.29. The business has a 50 day moving average price of $56.22 and a two-hundred day moving average price of $50.03. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. Bristol Myers Squibb’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of institutional investors have recently made changes to their positions in BMY. Norges Bank acquired a new position in Bristol Myers Squibb in the fourth quarter worth $1,947,272,000. AQR Capital Management LLC raised its holdings in shares of Bristol Myers Squibb by 172.6% during the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after purchasing an additional 16,332,924 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after buying an additional 10,195,775 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Bristol Myers Squibb by 428.5% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock valued at $523,599,000 after buying an additional 9,171,098 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Bristol Myers Squibb by 47.0% during the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock valued at $1,321,308,000 after buying an additional 7,837,485 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays initiated U.S. large‑cap biopharma coverage and included Bristol‑Myers Squibb among four preferred picks, arguing the sector could regain investor attention and highlighting BMY as a top choice. This institutional endorsement likely helped buying interest. Barclays launches U.S. biopharma coverage with four preferred picks
• Positive Sentiment: BMY reported completion of a mavacamten safety‑extension study update, which clarifies the long‑term safety profile for its hypertrophic cardiomyopathy program — a de‑risking event for a later‑stage asset and a potential long‑term revenue driver. BMY’s Mavacamten Safety Extension Wraps Up
• Positive Sentiment: Analyst/commentary pieces highlight BMY’s oncology franchise and new drug launches, noting cost cuts and a stronger 2026 outlook versus peers — reinforcing confidence in revenue stability and medium‑term growth. Bristol‑Myers Squibb: Oncology Franchise Remains A Core Strength
• Neutral Sentiment: Comparative analyst coverage (Zacks/Money pieces) argues BMY edges Merck in the 2026 setup due to product launches and cost actions — a relative positive versus peers but not new company‑specific catalysts. Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
• Neutral Sentiment: Coverage discussing an Iberdomide regulatory review and an AI partnership adds new angles to BMY’s mid‑cycle outlook; informative for pipeline expectations but not an immediate earnings swing. Iberdomide Review And AI Alliance Add New Angles To BMY Outlook
• Negative Sentiment: Zacks Research issued a series of downward revisions to several near‑term EPS estimates (notably Q1/Q2 2026 and FY2027 trims), which introduces caution around short‑term earnings momentum and could cap upside until upcoming results confirm guidance.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.